Clinical Trial Update: Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of Exendin 9-39 for postbariatric hypoglycemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postbariatric Hypoglycemia

Drugs mentioned

• Exendin 9-39 (exendin-9-39)

Snippet

Sponsor: Eiger BioPharmaceuticals | Conditions: Postbariatric Hypoglycemia | Phase 2 | Status: COMPLETED | Results posted: 2022-06-28